An open-label , randomized , phase II trial was conducted in @ centers ; @ patients were randomized ( @ : @ ) to either afatinib ( @ mg/day ) or cetuximab ( @ mg/m ( @ ) / week ) until disease progression or intolerable adverse events ( AEs ) ( stage I ) , with optional crossover ( stage II ) .